- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | PEGBIO CO-B Enters Joint R&D Collaboration With SN BioScience | 1 | AASTOCKS | ||
| PEGBIO Aktie jetzt für 0€ handeln | |||||
| Mi | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT JOINT R&D COLLABORATION WITH SN BIOSCIENCE ADVANCING THE LONG-ACTING DEVELOPMENT OF THREE NEXT-GENERATION ... | - | HKEx | ||
| 25.08. | PEGBIO CO-B (02565): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 13.08. | Lexaria geht Partnerschaft mit PegBio zur Verabreichung von GLP-1-Wirkstoffen ein | 6 | Investing.com Deutsch | ||
| 13.08. | Lexaria enters partnership with PegBio for GLP-1 drug delivery | 3 | Investing.com | ||
| 13.08. | Lexaria Bioscience Corp.: Lexaria Enters a Material Transfer Agreement With PegBio | 346 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into... ► Artikel lesen | |
| 13.08. | PEGBIO CO-B (02565): DATE OF BOARD MEETING | - | HKEx | ||
| 22.07. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT ISSUANCE OF THE FIRST BATCH OF COMMERCIAL PRESCRIPTIONS OF PAIDAKANG NATIONWIDE AND SATISFACTION OF THE CONDITIONS ... | - | HKEx | ||
| 10.07. | China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics | 2 | Yicai Global | ||
| 10.07. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NASDAQ-LISTED RANI THERAPEUTICS TO ADVANCE ORAL DELIVERY OF MULTIPLE INNOVATIVE METABOLIC ... | 3 | HKEx | ||
| 09.07. | Rani Therapeutics partners with PegBio on obesity drugs | 1 | Investing.com | ||
| 09.07. | Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates | 170 | GlobeNewswire (Europe) | ~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity... ► Artikel lesen | |
| 29.06. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT ... | - | HKEx | ||
| 26.06. | PEGBIO CO-B (02565): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.06. | PEGBIO CO-B (02565): COMPLETION OF THE H SHARE FULL CIRCULATION | 1 | HKEx | ||
| 24.06. | PEGBIO CO-B (02565): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 24.06. | PEGBIO CO-B (02565): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 24.06. | PEGBIO CO-B (02565): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON WEDNESDAY, JUNE 24, 2026; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR ... | 2 | HKEx | ||
| 05.06. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT PEGBIO RECEIVES FIRST ROYALTY PAYMENT OF HK$61 MILLION FROM TENRY PHARMACEUTICAL FOR VISEPEGENATIDE COMMERCIALIZATION ... | 1 | HKEx | ||
| 01.06. | PEGBIO CO-B (02565): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 24, 2026 | - | HKEx |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | 0,00 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | 0,00 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | +15,25 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | 0,00 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | -0,75 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | -0,57 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | +2,53 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| MODERNA | 125,24 | -2,20 % | Moderna stockt Wandelanleihe auf bis zu 3 Milliarden Dollar auf | Moderna hat die erst am Vortag angekündigte Wandelanleihe aufgrund der Nachfrage deutlich größer dimensioniert. Statt der zunächst geplanten 2,0 Milliarden Dollar platziert der Biotechkonzern nun unverzinsliche... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,270 | 0,00 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | +0,26 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,17 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -2,38 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,49 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? |
PEGBIO CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEGBIO CO LTD finden Sie auf Wallstreet Online.